Skip to main content

Table 2 Clinical and genetic data

From: Variant-beta luteinizing hormone is not associated with poor ovarian response to controlled ovarian hyperstimulation

Characteristic Poor ovarian response (n = 36) Controls (n = 98)
Age mean (95% CI) 34.0b (32.8-35.3) 32.4 (31.9-32.8)
BMI (kg/m 2 ) mean (95% CI) 26.5b (24.3-28.7) 23.8 (23.1-24.5)
No. of patients of other ethnicities than Caucasian (%) 3 (8.3) 4 (4.1)
First time COH (%) 32 (88.9) 83 (84.7)
Early follicular phase s-FSH a mean (95% CI) 6.0 (5.3-6.7) 5.8 (5.4-6.3)
First dose of rFSH (IU) mean (95% CI) 160 (152–168) 159 (155–162)
Duration of rFSH medication (Days) mean (95% CI) 10.8 (10.2-11.3) 10.9 (10.8-11.1)
Total dose of rFSH (IU) mean (95% CI) 1739 (1616–1863) 1738 (1692–1784)
Oocytes retrieved mean (95% CI) 1.5b (1.1-2.0) 9.0 (8.5-9.5)
No. of embryos transferred mean (95% CI) 0.6b (0.4-0.9) 1.6 (1.5-1.7)
Live births (% of started COH) 2b (6) 45 (46)
No. of patients with v-betaLH (%) 4 (11) 17 (17)
No. of alleles with v-betaLH (%) 4 (6) 18 (9)
  1. aNot registered for all patients. N registered for the respective groups: 32, 76.
  2. bStatistically significant (p-value of <0.05) difference compared to controls by student’s t-test or chi square.